About The Study: From 2020 to 2025, prior authorization for glucagon-like peptide-1 receptor agonists (GLP-1RAs) became near universal and out-of-pocket costs rose substantially in 2025, as plans increasingly required coinsurance. Although the rise in prior authorization may reflect efforts to curtail off-label GLP-1RA use, recent increases in out-of-pocket costs likely resulted from broader shifts to coinsurance affecting many high-cost drugs.

Living in a resource-deprived area may increase your risk of certain psychiatric conditions, according to a recent study from the University of Georgia.